Figure 4
From: RFC2: a prognosis biomarker correlated with the immune signature in diffuse lower-grade gliomas
Association between RFC2 expression and overall survival (OS) across cancers in TCGA cohort. (A) Forest plot showing the correlation of RFC2 expression with OS in 33 types of cancer. (B–I) Kaplan–Meier survival analyses displaying the relationships of RFC2 expression with OS in different cancer types, including glioblastoma (GBM) (B), diffuse lower-grade gliomas (LGG) (C), adrenocortical carcinoma (ACC) (D), cervical cancer (CESC) (E), kidney chromophobe (KICH) (F), kidney renal clear cell carcinoma (KIRC) (G), lung adenocarcinoma (LUAD) (H), and ocular melanomas (UVM) (I).
